Evidence map›Paper›PMID 21738077›Full record

Trial reportMenopause (New York, N.Y.)2011

The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women: results and lessons for future research.

Gregory A Plotnikoff, Kenji Watanabe, Carolyn Torkelson, June La Valleur, David M Radosevich

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Menopause (New York, N.Y.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review.BJOG : an international journal of obstetrics and gynaecology · 2020
    Pooled it
  3. Pooled it
  4. Chinese herbal medicine for menopausal symptoms.The Cochrane database of systematic reviews · 2016
    Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Climacteric symptoms in postoperative patients among endometrial cancer, cervical cancer, and ovarian cancer: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  10. Article
  11. Article
  12. The Multiple Pharmacologic Functions and Mechanisms of Action of Guizhi Fuling Formulation.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Gregory A PlotnikoffAllina Center for Health Care Innovation, Abbott Northwestern Hospital, Minneapolis, MN 55407-3799, USA. plotnikoff@allina.com
Kenji Watanabe
Carolyn Torkelson
June La Valleur
David M Radosevich
University of Minnesota Medical Center · USKeio University · JP

Funding

YOUTH DRUG ABUSE, ADHD, AND RELATED DISRUPTIVE DISORDERSM01RR000400 · NCRR · UNIVERSITY OF MINNESOTA TWIN CITIES · PI KOTLYAR, MICHAEL · 1985 to 2009
$33.7M
NCRR NIH HHS M01 RR000400NCRR NIH HHS M01-RR00400
6 · The paper itself

Abstract

objectiveThe aim of this study was to assess the efficacy of TU-025, keishibukuryogan, a Japanese prescription herbal medicine used for hot flash management, in American women.

methodsThis randomized, double-blind, placebo-controlled, phase II trial enrolled 178 postmenopausal women aged 45 to 58 years with a Mayo hot flash score greater than 28 per week who met other inclusion criteria. After a 1-week placebo run-in period, participants were randomly assigned placebo, or 7.5 g/day, or 12.5 g/day groups, for 12 weeks. Primary and secondary outcomes were measured using the Mayo Clinic Hot Flash Diary, the Greene Climacteric Index, and the Pittsburgh Sleep Quality Index.

resultsAt 3 months, hot flash scores, climacteric symptoms, and sleep quality improved by 34% in the placebo group, 40% in the 7.5 g/day group, and 38% in the 12.5 g/day group. (P < 0.001). However, the differences in changes between groups were not statistically significant (P = 0.990). Diarrhea unexpectedly developed in 20% of participants receiving active medication.

conclusionsFor American women, unlike the clinical experience for Japanese women, TU-025 did not significantly reduce the frequency and severity of hot flash symptoms, improve climacteric symptoms, or benefit sleep quality. This study identified several potentially significant methodological factors to be considered in future scientific assessments of traditional Asian medicines.

Indexed as

Severity of Illness IndexDouble-Blind MethodDrugs, Chinese HerbalFemaleHealth Status IndicatorsHot FlashesHumansPhytotherapyPlants, MedicinalPostmenopauseQuality of LifeTreatment OutcomeDrugs, Chinese Herbalkeishibukuryogan

Identifiers

PMID21738077
PMCPMC3181094
OpenAlexW1985845369

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.